Literature DB >> 22900939

Synthesis and scalable conversion of L-iduronamides to heparin-related di- and tetrasaccharides.

Steen U Hansen1, Gavin J Miller, Marek Baráth, Karl R Broberg, Egle Avizienyte, Madeleine Helliwell, James Raftery, Gordon C Jayson, John M Gardiner.   

Abstract

A diastereomerically pure cyanohydrin, preparable on kilogram scale, is efficiently converted in one step into a novel L-iduronamide. A new regioselective acylation of this iduronamide and a new mild amide hydrolysis method mediated by amyl nitrite enables short, scalable syntheses of an L-iduronate diacetate C-4 acceptor, and also L-iduronate C-4 acceptor thioglycosides. Efficient conversions of these to a range of heparin-related gluco-ido disaccharide building blocks (various C-4 protection options) including efficient multigram access to key heparin-building block ido-thioglycoside donors are described. A 1-OAc disaccharide is converted into a heparin-related tetrasaccharide, via divergence to both acceptor and donor disaccharides. X-ray and NMR data of the 1,2-diacetyl iduronate methyl ester and the analogous iduronamide show that while both adopt (1)C(4) conformations in solution, the iduronate ester adopts the (4)C(1) conformation in solid state. An X-ray structure is also reported for the novel, (4)C(1)-conformationally locked bicyclic 1,6-anhydro iduronate lactone along with an X-ray structures of a novel distorted (4)C(1) iduronate 4,6-lactone. Deuterium labeling also provides mechanistic insight into the formation of lactone products during the novel amyl nitrite-mediated hydrolysis of iduronamide into the parent iduronic acid functionality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22900939     DOI: 10.1021/jo300722y

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  7 in total

1.  Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling.

Authors:  Claire L Cole; Graham Rushton; Gordon C Jayson; Egle Avizienyte
Journal:  J Biol Chem       Date:  2014-02-22       Impact factor: 5.157

2.  Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies.

Authors:  Steen U Hansen; Gavin J Miller; Claire Cole; Graham Rushton; Egle Avizienyte; Gordon C Jayson; John M Gardiner
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

3.  Synthesis of a heparin-related GlcN-IdoA sulfation-site variable disaccharide library and analysis by Raman and ROA spectroscopy.

Authors:  Gavin J Miller; Steen U Hansen; Marek Baráth; Christian Johannessen; Ewan W Blanch; Gordon C Jayson; John M Gardiner
Journal:  Carbohydr Res       Date:  2014-07-14       Impact factor: 2.104

4.  Single-Molecule Fluorescence Detection of a Synthetic Heparan Sulfate Disaccharide.

Authors:  Charlotte E Dalton; Steven D Quinn; Aidan Rafferty; Michael J Morten; John M Gardiner; Steven W Magennis
Journal:  Chemphyschem       Date:  2016-09-14       Impact factor: 3.102

5.  Making the longest sugars: a chemical synthesis of heparin-related [4] n oligosaccharides from 16-mer to 40-mer.

Authors:  Steen U Hansen; Gavin J Miller; Matthew J Cliff; Gordon C Jayson; John M Gardiner
Journal:  Chem Sci       Date:  2015-07-24       Impact factor: 9.825

6.  A latent reactive handle for functionalising heparin-like and LMWH deca- and dodecasaccharides.

Authors:  Gavin J Miller; Karl R Broberg; Claire Rudd; Madeleine R Helliwell; Gordon C Jayson; John M Gardiner
Journal:  Org Biomol Chem       Date:  2015-09-18       Impact factor: 3.876

7.  Synthetic heparan sulfate dodecasaccharides reveal single sulfation site interconverts CXCL8 and CXCL12 chemokine biology.

Authors:  Gordon C Jayson; Steen U Hansen; Gavin J Miller; Claire L Cole; Graham Rushton; Egle Avizienyte; John M Gardiner
Journal:  Chem Commun (Camb)       Date:  2015-08-03       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.